Clinical trials: Neoplasms, Metastatic
Malignant Melanoma
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in…
- Trial name
- NCT01656642
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Malignant Melanoma, Squamous Cell Carcinoma of Skin
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with…
- Trial name
- NCT04913220
- Testing
- THOR-707, Cemiplimab
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Sanofi
Colorectal Cancer
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent…
- Trial name
- NCT00017082
- Testing
- oxaliplatin
- Where
- 10 sites in United States
- Sponsor
- Prologue Research International
Neoplasms
A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
This open-label 2-arm study will assess the pharmacokinetics, pharmacodynamics, safety and efficacy of RO5429083 in patients with metastatic and/or locally advanced CD44-expressing malignant solid tumors.
- Trial name
- NCT01358903
- Testing
- RO5429083
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen
To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer
- Trial name
- NCT00191269
- Testing
- gemcitabine
- Where
- 13 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
- Trial name
- NCT03437083
- Testing
- Eribulin mesylate
- Where
- 14 sites in South Korea
- Volunteers
- 340 people
- Sponsor
- Eisai Korea Inc.
Advanced or Metastatic Non-small Cell Lung Cancer
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human…
- Trial name
- PALOMA-3 (NCT05388669)
- Testing
- Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
- Where
- 187 sites in United States, Argentina and 18 more
- Volunteers
- 418 people
- Sponsor
- Janssen Research & Development, LLC
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic…
- Trial name
- NCT04785820
- Testing
- Lomvastomig, Tobemstomig, Nivolumab
- Where
- 52 sites in Argentina, Brazil and 16 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Colorectal Neoplasm
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany.
- Trial name
- RECORA (NCT01959269)
- Testing
- Regorafenib (Stivarga, BAY 73-4506)
- Where
- Germany
- Volunteers
- 483 people
- Sponsor
- Bayer
Gastric Cancer, Gastroesophageal Junction Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC)…
- Trial name
- NCT06731478
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab
- Where
- 250 sites in United States, Argentina and 24 more
- Volunteers
- 726 people
- Sponsor
- Daiichi Sankyo
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Advanced Ovarian Cancer, Metastatic Breast Cancer
Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients
To characterize the pharmacokinetic profile of pegylated liposomal doxorubicin formulations, a multicenter, randomized, two-period crossover study was conducted in 74 patients with advanced ovarian cancer or metastatic breast…
- Trial name
- NCT07648940
- Testing
- Doxopeg® - Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL), Caelyx® - Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL)
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
Carcinoma, Renal Cell
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive…
- Trial name
- NCT00130897
- Testing
- Sutent
- Where
- 271 sites in United States, Argentina and 48 more
- Sponsor
- Pfizer
Prostate Cancer
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
- Trial name
- PLATO (NCT01995513)
- Testing
- Enzalutamide, Abiraterone, Prednisone
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Solid Tumor
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors
This study is a single-center, single-arm phase I clinical trial. A total of 30 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study.
- Trial name
- GT201 (NCT05430360)
- Testing
- GT201
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Grit Biotechnology
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Breast Cancer
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
The primary objective is: To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: To determine…
- Trial name
- NCT00917748
- Testing
- DOCETAXEL(XRP6976) + MODAFINIL, Modafinil
- Where
- Australia
- Volunteers
- 84 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.